Jenna Cohen

Bio:

Jenna Cohen is most recently the Vice President, Investor Relations and Global Business Communications at Blueprint Medicines, a Sanofi Company, a global biotechnology company headquartered in Cambridge, MA. During her tenure at Blueprint, Jenna oversaw a team that was responsible for developing and sharing the story of Blueprint's strategic vision to drive value among investors, media, and other external audiences. She worked alongside an executive team as they navigated a biotech bear market, the global launch of lead asset AYVAKIT® (avapritinib) in a rare disease called systemic mastocytosis, portfolio strategy shifts, and ultimately a $9.5 billion dollar acquisition by Sanofi, which closed in July 2025. She previously served in various roles within commercial market access, government affairs, and policy, most recently at Gilead Sciences in the San Francisco Bay Area, and prior to that at Avalere Health in Washington, DC. Jenna received her B.S. in Biological Sciences and minor in Communications at Cornell University.